RAPT Therapeutics Announces $150 Million Private Placement

Core Viewpoint - RAPT Therapeutics, Inc. has announced a private placement of securities to raise approximately $150 million for research and development and general corporate purposes [1][2]. Group 1: Private Placement Details - The company will issue 100,000,000 shares of common stock at a price of $0.85 per share and pre-funded warrants to purchase up to 76,452,000 shares at a price of $0.8499 per warrant [1]. - The private placement is expected to close on or about December 27, 2024, subject to customary closing conditions [1]. - The pre-funded warrants will have an exercise price of $0.0001 per share and will be immediately exercisable [1]. Group 2: Use of Proceeds - Net proceeds from the private placement are intended to fund the research and development of the company's pipeline and for general corporate purposes [2]. Group 3: Company Overview - RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on developing therapies for inflammatory diseases with significant unmet needs [3]. - The company utilizes a proprietary discovery and development platform to advance both biologics and selective small molecules targeting critical immune drivers [3]. Group 4: Placement Agent and Investors - Leerink Partners is acting as the sole placement agent for the private placement [3]. - The placement was led by The Column Group and TCGX, with participation from various investors including BVF Partners LP, Deep Track Capital, and others [6].